Hunan Er-Kang Pharmaceutical Co., Ltd (SHE:300267)

China flag China · Delayed Price · Currency is CNY
3.840
-0.100 (-2.54%)
Mar 19, 2026, 3:04 PM CST
Market Cap7.92B +34.7%
Revenue (ttm)1.29B +8.4%
Net Income-308.33M
EPS-0.15
Shares Out2.06B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume46,724,606
Average Volume92,677,320
Open4.000
Previous Close3.940
Day's Range3.810 - 4.000
52-Week Range2.140 - 4.830
Beta0.43
RSI47.75
Earnings DateApr 23, 2026

About SHE:300267

Hunan Er-Kang Pharmaceutical Co., Ltd engages in the research and development, production, and sale of pharmaceutical excipients, APIs and finished drugs in China and internationally. The company offers various APIs, such as glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. It also provides finished drugs, including sulbenicillin sodium for injection and compound liquorice tablets. In addition, the company offers conventional pharmaceutica... [Read more]

Sector Healthcare
Founded 2003
Employees 1,453
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300267
Full Company Profile

Financial Performance

In 2024, SHE:300267's revenue was 1.14 billion, a decrease of -36.09% compared to the previous year's 1.78 billion. Losses were -373.37 million, 91.2% more than in 2023.

Financial Statements